(Total Views: 916)
Posted On: 05/03/2021 5:24:09 PM
Post# of 155780
IMO, It looks like they did mention it in the last PR at the bottom:
Nader Pourhassan, Ph.D., President and Chief Executive Officer, commented, “Our multi-pathway approach to exploring all potential indications for leronlimab is proving to be very encouraging. We look forward to accelerating our efforts in the oncology field with leronlimab. We are equally excited to update our stockholders on Wednesday, especially concerning the potential use of leronlimab in treating COVID-19 in severe, critical, and long-hauler populations.”
https://www.cytodyn.com/newsroom/press-releas...eated-with
IMO
Nader Pourhassan, Ph.D., President and Chief Executive Officer, commented, “Our multi-pathway approach to exploring all potential indications for leronlimab is proving to be very encouraging. We look forward to accelerating our efforts in the oncology field with leronlimab. We are equally excited to update our stockholders on Wednesday, especially concerning the potential use of leronlimab in treating COVID-19 in severe, critical, and long-hauler populations.”
https://www.cytodyn.com/newsroom/press-releas...eated-with
IMO
(2)
(0)
The fault-finder will find faults even in paradise. -Henry David Thoreau
